AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US

Core Viewpoint - AstraZeneca shareholders have approved a direct listing of the company's shares on the New York Stock Exchange, which will provide access to a deeper capital pool [1] Group 1 - The approval by shareholders marks a significant step for AstraZeneca in enhancing its market presence [1] - The direct listing is expected to facilitate greater liquidity and investment opportunities for the company [1]